首页> 外文OA文献 >Advances in progenitor cell therapy using scaffolding constructs for central nervous system injury.
【2h】

Advances in progenitor cell therapy using scaffolding constructs for central nervous system injury.

机译:使用支架构建物治疗中枢神经系统损伤的祖细胞治疗的进展。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Traumatic brain injury (TBI) is a major cause of morbidity and mortality in the United States. Current clinical therapy is focused on optimization of the acute/subacute intracerebral milieu, minimizing continued cell death, and subsequent intense rehabilitation to ameliorate the prolonged physical, cognitive, and psychosocial deficits that result from TBI. Adult progenitor (stem) cell therapies have shown promise in pre-clinical studies and remain a focus of intense scientific investigation. One of the fundamental challenges to successful translation of the large body of pre-clinical work is the delivery of progenitor cells to the target location/organ. Classically used vehicles such as intravenous and intra arterial infusion have shown low engraftment rates and risk of distal emboli. Novel delivery methods such as nanofiber scaffold implantation could provide the structural and nutritive support required for progenitor cell proliferation, engraftment, and differentiation. The focus of this review is to explore the current state of the art as it relates to current and novel progenitor cell delivery methods.
机译:在美国,颅脑外伤(TBI)是发病率和死亡率的主要原因。当前的临床治疗集中在优化急性/亚急性脑环境,最大程度地减少持续的细胞死亡以及随后的剧烈康复以减轻TBI导致的长期身体,认知和社会心理缺陷。成人祖细胞治疗已经在临床前研究中显示出了希望,并且仍然是科学研究的重点。成功地翻译大量临床前工作的基本挑战之一是将祖细胞运送到目标位置/器官。经典使用的媒介物(例如静脉内和动脉内输注)显示出低的植入率和远端栓塞的风险。诸如纳米纤维支架植入的新型递送方法可以提供祖细胞增殖,移植和分化所需的结构和营养支持。这篇综述的重点是探索与当前和新颖的祖细胞递送方法有关的当前技术水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号